Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neurotrophin-3 (dfb6c7)
- Development stage
- Unknown
- Lead developer
- Guna
- Modality
- Hormonal Peptides → Native Peptides → Peptides, Hormones & Growth Factors → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Neurotrophin-3 (low-dose) is a therapeutic formulation developed by **Guna** using their proprietary **Sequential Kinetic Activation (SKA)** technology. This approach, part of **Physiological Regulating Medicine (PRM)**, delivers signaling molecules like neurotrophin-3 (NT3) at extremely low, physiological concentrations (typically in the picogram/milliliter range). The formulation is designed to provide neurotrophic support to retinal cells, aiming to improve visual function and slow the progression of **retinal atrophy** and other degenerative retinal diseases. By mimicking endogenous signaling, low-dose NT3 is intended to activate high-affinity TrkC receptors on retinal neurons, promoting cell survival, plasticity, and neuroprotection. It has been investigated in Phase 2 clinical settings, often as part of a multi-component low-dose medicine protocol for retinal degeneration.
- Other names
- Neurotrophin-3Neurotrophin3Neurotrophin 3Low-dose neurotrophin-3NT3NT-3NT 3
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)
Beyond the preview
Go deeper on neurotrophin-3 (dfb6c7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neurotrophin-3 (dfb6c7).